Large panel (300+ genes) liquid biopsy assays hold the promise of delivering comprehensive genomic insights from a simple blood draw, but many laboratories hesitate to bring this in house due to perceived cost, technical and operational challenges.
Recent advances are rapidly changing this landscape. Improvements in library preparation workflows, decreasing cost per sample—even at smaller batch sizes—and compatibility with mid-throughput sequencing instruments are making liquid biopsy CGP research more accessible than ever. Compared to FFPE tissue, plasma workflows can also offer shorter turnaround times and streamlined laboratory processes, enabling laboratories to deliver genomic insights when tissue is limited, unavailable, or results are needed quickly.
In this webinar, Dr. Gang Zheng MD, PhD, will share experience from the Mayo Clinic laboratory, how the lab approaches liquid biopsy and recent implementation data of a liquid biopsy assay to enable comprehensive genomic profiling (CGP).
Attendees will learn:
An introduction to liquid biopsy
What liquid biopsy options Mayo Clinic offers and why
Why Mayo Clinic decided to bring a large panel liquid biopsy research assay in house
Performance of TSO 500 ctDNA v2 across key variant classes (SNVs, Indels, CNVs, Rearrangements, large gene signatures) and inputs such as blood and cerebral spinal fluid (CSF)
Analytical accuracy and reproducibility supporting deployment
Approaches to CHIP detection and filtering to ensure confident variant reporting
Concordance to solid tumor CGP FFPE tissue assay
Comparative performance insights versus a liquid biopsy send-out assay
For Research Use Only. Not for use in diagnostic procedures.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
